You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Loading...

About This Product

Daclatasvir (NatDac) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.

  • Manufacturer | Marketer

    Natco Pharma Ltd.

  • Storage

    Store below 30°

  • Salt Composition

    Daclatasvir

details

U.S. Food and Drug Administration approved NatDac (Daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections on July 24, 2015 . NATDAC (Daclatasvir) is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.

Dosage and Administration :Daclatasvir Download Daclatasvir Prescribing information NatDac (Daclatasvir) is available in 30 and 60mg tablets, and the usual dose is 60mg once daily with or without food. NatDac (Daclatasvir) must be used in combination with other hepatitis C medications and is not effective if taken alone.

People with HCV genotypes 1 or 4 who are being treated for the first time and do not have liver cirrhosis should take daclatasvir plus sofosbuvir for 12 weeks. Due to limited clinical trial data, there is still uncertainty about the best way to treat people with genotypes 2, 3 or 4.